TABLE 3.
Assessment of the Altered Protein Expression
| Neuroanatomic Region, Section | Staining | ||||
|---|---|---|---|---|---|
| H&E | HPτ | Aβ | αS | TDP43 | |
| Frontal cortex, gyrus medius | X | 3 | |||
| Temporal cortex, gyrus medius | X | 2 | 4 | 2 | |
| Gyrus cinguli, anterior | X | 3 | |||
| Parietal cortex, inferior | X | 1* | 4 | ||
| Pre-/post central cortex | X | ||||
| Occipital cortex | X | 3 | |||
| Hippocampus anterior | X | 1 | 1 | ||
| Hippocampus posterior | X | 1 | 2 | 2 | 1 |
| Basal forebrain, incl. amygdala | X | 2 | 1 | 1 | |
| Striatum | X | ||||
| Thalamus | X | ||||
| Mesencephalon, incl. substantia nigra | X | 3 | 1 | ||
| Pons, incl. locus coeruleus | X | 1 | |||
| Medulla, incl. motor nucleus of vagus | X | 1 | 1 | ||
| Vermis | X | ||||
| Cerebellum | X | 4 | |||
H&E, hematoxylin and eosin; HPτ, hyperphosphorylated-τ; Aβ, β-amyloid; αS, α-synuclein; TDP43, transactive response DNA binding protein 43.
Screening of the protein expression was initiated with the assessment of a region numbered as 1 in the table. If immunoreactivity was observed, staining was then carried out on the other regions in ascending order as numbered.
*Assessment of cerebral amyloid angiopathy.